Orexo AB publ

International Overdose Awareness Day, tomorrow on 31 August, is an opportunity for people across the globe to reflect on the many lives being destroyed by #opioids, and the grief of their loved ones. In the US opioids, and not at least synthetic opioids, are behind the vast majority of the fatal overdoses. It’s more IMPORTANT than ever to consider how we can prevent more BROKEN LIVES AND FAMILIES 💜 #rescuemedications #HIGHDOSE #OX124 #SDG3.5

Orexo is developing a needle-free epinephrine medication, OX640, with nasal delivery that is free from antioxidants and preservatives. Thanks to the first-class powder-based drug delivery technology, AmorphOX®, OX640 has the potential to significantly increase the stability and shelf-life comparing to current treatments. Learn more about OX640: ⏩Listen to our SVP and Head of R&D presenting at the Drug Formulation & Bioavailability event in Copenhagen on Aug. 28 (see below). ⏩For details related to the positive data showed in the first clinical trial -https://shorturl.at/taDZP #anaphylaxis #drugdelivery #science

At Orexo, we are proud to be part of a small group of Swedish life science companies that has TRANSITIONED from being solely an R&D company to also commercializing drugs. This journey would not have been possible without the amazing ECOSYSTEM of investors, academia, advocacy organizations, and a cluster of small and medium-sized industry companies. All are supported by federal initiatives to help the sector thrive. Today, the Swedish LIFE SCIENCE INDUSTRY is an important part of the Swedish economy, becoming a fundamental industry alongside more traditional sectors. We are honored to be mentioned in SwedenBIO article: "Sweden and Danish Life Science experience substantial growth." https://lnkd.in/dmsfsTMB #Lifescience #Science #Transformation #Leadership

Federal departments and agencies need to do more to stop the supply of illicit fentanyl and other synthetic opioids in the US, according to the new National Security Memorandum, issued by President Biden. President Biden and Vice President Harris have asked Congress to put legislation in place to increase the penalties for people who traffic drugs and exploit legal loopholes in the US. The “Detect and Defeat” Counter-Fentanyl Proposal would establish a nationwide pill press and tableting machine registry, making it easier to track these tools and what they’re being used for. This would help to stop the making of fake fentanyl pills, which are responsible for many unintended overdoses in the US, particularly among young people. In 2023, the DEA seized 75 million pills containing fentanyl. Read more about how these pills are impacting young people in the US and what needs to be done to change the landscape: https://lnkd.in/gsW6GC3Z

It’s National Parents’ Day in the US this Sunday, 28 July. Raising children is an enormous responsibility, and the celebration is a way to recognize the role of mothers and fathers in parenting. At Orexo, we know that families affected by substance misuse may be struggling while others are celebrating. We also know that help can make all the difference. Read Dominique’s story here: https://lnkd.in/ggUr_-FF If you or someone you love needs support, please talk to someone you trust. #NationalParentsDay #OUD

Yesterday, we released our Q2 Interim Report. In the period, net revenues for our main product in the US market increased by 2% (14% QoQ). For the 3rd consecutive quarter, we reported a positive EBITDA of SEK 5 million, despite higher legal costs and increased costs for preparing the US launch of OX124, our high-dose rescue medication for opioid overdose.* Operationally, we also saw a high level of activity in our pipeline with a focus on advancing the drug candidates based on our first-class drug delivery platform AmorphOX. We are also pleased that our sustainability efforts yet another time have been recognized by an external partner. This time by EcoVadis. After the reporting period and in regards to the OX124 NDA filing, FDA requested additional technical data on the final commercial product and data from a new human factor (HF) study. A new HF study was successfully conducted in early July and we will continue taking the necessary actions to swiftly provide the agency with the additional information. *The full-year financial guidance remains unchanged. Read the full report here: https://lnkd.in/gPq5Agg3

We are thrilled that our sustainability work once again* has been recognized. This time by EcoVadis, one of the world's most trusted sustainability assessment providers. Among the 70.000 businesses reviewed annually by EcoVadis, Orexo AB is ranked among the top 5%. Nikolaj Sørensen, President and CEO, of Orexo, said, “Achieving this rating is a privilege and we will continue setting ambitious goals in our active pursuit of an even more sustainable and inclusive future for everyone. This is central to our values-based approach to growth and underpins optimal outcomes for patients, investors, the company and society more broadly.” * Earlier this year, Orexo's sustainability efforts were successfully evaluated by Morningstar Sustainalytics, allowing us to refinance our corporate bond with a SOCIAL bond. #SDG3 #impactfull #UNglobalcompact Read PR here: https://lnkd.in/dHxq5r54

When Jonas Sävmarker joined Orexo, his goal was to create a treatment to help save the lives of people suffering from opioid overdoses. His research pioneered AmorphOX®, Orexo’s world-class drug delivery platform. In this interview, Jonas talks about his natural curiosity, why he enjoys working at Orexo and how his role takes him all over the world. Meet Jonas, the man behind the science: https://lnkd.in/gcBSH6-m #AmorphOX #Science

At one of our internal breakfasts for our employees in Uppsala, Sweden, we recently welcomed a guest from the Academy. Fred Nyberg, Professor in Biological Research on Drug Dependence at Uppsala University, joined us to talk about the prevalence of synthetic opioids with a focus on the US, why they are life-threatening, and the need for more powerful overdose drugs. The timing could not be better as we are approaching an approval of OX124 - a high-dose rescue medication for opioid overdoses. #SDG3 #opioidcrisis #OX124 #amorphOX

Orexo has long experience in successful collaborations, which has enabled the development and launch of novel products, offering improved treatment options for patients worldwide. Image below: Our colleagues Petter Wereen and "Boz" Coburn attending the Bio International Convention, where they were talking to pharma companies and other industry professionals with a focus on our scalable drug delivery technology AmorphOX and the therapies that are in our pipeline. #drugdevelopment #OX640 #largemolecules